You are here
NeuroMetrix Reports Presentation of Clinical and Scientific Data on Quell Wearable Pain Relief Technology at PAINWeek 2018 National Conference
WALTHAM, Mass., Aug. 28, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO), today reported that it will present three scientific posters at the upcoming PAINWeek 2018 National Pain Conference to be held in Las Vegas, NV, September 4-8.
The PAINWeek 2018 Abstract Book may be accessed here. The three NeuroMetrix abstracts are:
Pilot Study of Fixed-Site High-Frequency Transcutaneous Electrical Nerve Stimulation in Fibromyalgia. Quell® efficacy was evaluated in a 30-day open-label study of 12 subjects with confirmed fibromyalgia. A majority of subjects demonstrated clinically meaningful improvement in Fibromyalgia impact and pain level. This study was conducted in collaboration with Mauro Zappaterra, M.D., Ph.D., of Synovation Medical Group. Abstract #81
Real-Word Effectiveness of Fixed-Site High-Frequency Transcutaneous Electrical Nerve Stimulation in Chronic Low Back Pain. Quell effectiveness was evaluated in a 10-week real-world retrospective study using propensity score matching. 843 Quell users with chronic low back pain (CLBP) were evaluated using the Quell Health Cloud. Regular Quell use was found effective in improving pain outcomes in CLBP. Abstract #107
Effectiveness of Fixed-Site High-Frequency Transcutaneous Electrical Nerve Stimulation among Individuals with Chronic Pain and Abnormal Sleep. In this real-world retrospective study of 2034 Quell users from the Quell Health Cloud, one-quarter had substantially impaired sleep based on the device’s objective sleep tracking. In addition, Quell effectiveness, over 10-weeks, was found to be generally independent of baseline sleep characteristics. Abstract #122
"We are pleased to present important and interesting clinical and scientific data at this year’s PAINWeek conference. These poster presentations reflect our ongoing commitment to building the clinical and scientific foundation for the use of non-invasive neurostimulation, and Quell specifically, to treat chronic pain," said Shai N. Gozani, M.D., Ph.D., President and CEO of NeuroMetrix. "Two of the studies inform use of Quell in Fibromyalgia and Chronic Low Back Pain, which according to our Quell Health Cloud data are among the most common applications for Quell. The third poster demonstrates that Quell effectiveness is not diminished in users with poor sleep at onset of therapy. This is an important finding given the reciprocal interactions between poor sleep and chronic pain. The study also highlighted the importance of sleep monitoring and treatment personalization."
Quell is an advanced, wearable technology for treating chronic pain. It can be worn during the day while active and at night while sleeping. Quell is drug-free and has been cleared by the FDA for treatment of chronic pain without a prescription. Quell has been shown in multiple clinical studies to relieve chronic pain and, in a published study, 4 out of 5 users reported improvement in chronic pain. Quell users can personalize and manage therapy discreetly via the Quell app. Quell also offers health tracking relevant to chronic pain sufferers including pain, sleep, activity, and gait. Quell users can synchronize their data with the Quell Health Cloud, which provides customized feedback and powers one of the world’s largest chronic pain databases. Quell is available online and through select retailers. Visit QuellRelief.com for more information.
NeuroMetrix is an innovation driven healthcare company combining neurostimulation and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The company's lead product is Quell, an over-the-counter wearable therapeutic device for chronic pain. The company also markets DPNCheck®, a rapid point-of-care test for diabetic neuropathy, which is the most common long-term complication of Type 2 diabetes. For more information, please visit NeuroMetrix.com.
Source: NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and Chief Financial Officer